(0.34%) 5 117.23 points
(0.33%) 38 366 points
(0.38%) 15 989 points
(-0.95%) $83.05
(5.56%) $2.03
(0.34%) $2 355.10
(0.44%) $27.66
(4.05%) $959.45
(-0.25%) $0.932
(-0.40%) $10.98
(-0.55%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 5.42%
@ $23.28
発行日: 14 2月 2024 @ 23:30
リターン: 0.56%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 0.28 %
Live Chart Being Loaded With Signals
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States...
Stats | |
---|---|
本日の出来高 | 200 409 |
平均出来高 | 1.13M |
時価総額 | 2.42B |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $0.180 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 24.90 |
ATR14 | $0.0360 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Mahoney David L | Buy | 27 806 | Common Stock |
2024-04-10 | Mahoney David L | Buy | 30 000 | Common Stock |
2024-04-10 | Mahoney David L | Sell | 2 194 | Common Stock |
2024-04-10 | Mahoney David L | Sell | 27 806 | Common Stock |
2024-04-10 | Mahoney David L | Sell | 30 000 | Stock option (right to buy) |
INSIDER POWER |
---|
62.30 |
Last 97 transactions |
Buy: 1 925 494 | Sell: 448 997 |
ボリューム 相関
Corcept Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
SVAC | 0.941 |
PAIC | 0.916 |
TLGT | 0.913 |
GETVV | 0.897 |
RMRM | 0.897 |
SVOK | 0.891 |
MTSL | 0.888 |
CERC | 0.865 |
GOODM | 0.854 |
FCFS | 0.838 |
10 最も負の相関 | |
---|---|
AMRB | -0.968 |
NETE | -0.941 |
MMAC | -0.919 |
PFG | -0.901 |
LINC | -0.887 |
FFBW | -0.872 |
SRAC | -0.871 |
REG | -0.865 |
IOSP | -0.865 |
NOVT | -0.861 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Corcept Therapeutics Inc 相関 - 通貨/商品
Corcept Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $482.38M |
総利益: | $475.89M (98.66 %) |
EPS: | $1.020 |
FY | 2023 |
収益: | $482.38M |
総利益: | $475.89M (98.66 %) |
EPS: | $1.020 |
FY | 2022 |
収益: | $401.86M |
総利益: | $396.47M (98.66 %) |
EPS: | $0.950 |
FY | 2021 |
収益: | $365.98M |
総利益: | $360.70M (98.56 %) |
EPS: | $0.970 |
Financial Reports:
No articles found.
Corcept Therapeutics Inc
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。